The question behind the headline
A treatment decision has more than one time horizon. There is the first prescription, the period when weight changes, and the months after treatment is interrupted or ends. The STEP 1 extension is useful because it looks at that third period. It gives a reason to discuss the future before a coverage change or an unaffordable renewal makes the decision for you. It does not tell an individual patient when to stop, how to taper, or what a replacement prescription should be.
The original trial studied adults without diabetes, with obesity or overweight plus a weight-related condition. This exploratory extension followed 327 participants after 68 weeks of semaglutide 2.4 mg weekly or placebo. Both study medication and the structured lifestyle intervention ended; follow-up continued for another year.[1]
Read the change over time
In the extension subset, average loss with semaglutide was 17.3% at week 68. Participants subsequently regained 11.6 percentage points, leaving average weight 5.6% below the original starting weight at week 120. Most measured cardiometabolic improvements moved back toward baseline. These are group results, with substantial individual variation.[1]
Two different chapters of one study
The phrase “two-thirds regained” refers to the share of the earlier weight loss that returned. It does not mean participants gained two-thirds of their entire body weight. Nor does a group average mean every person returned to the same point. Separating the starting reference from the amount lost makes this finding easier to discuss without turning it into an alarming prediction.
For a different withdrawal design, read the tirzepatide maintenance study. Our ongoing care plan helps turn the longer horizon into questions for a provider. If treatment is continuing but weight is steady, see semaglutide weight plateaus.
Where the evidence stops
| What to separate | What it means for your reading |
|---|---|
| Withdrawal versus continuation | This extension did not newly randomize participants to continue treatment or stop. |
| Medication versus support | Both ended together, so their separate contributions cannot be isolated here. |
| An average versus your future | The result is a study summary, not an individual forecast. |
| Stopping versus tapering | The design does not establish a taper, lower dose or alternative medication plan. |
An extension is also a narrower window than the original trial. The people available for follow-up need not represent everyone who begins treatment in ordinary care. The study therefore belongs in the discussion, but it cannot replace a clinician’s assessment of your treatment response, tolerability, other conditions or priorities. It also did not compare subscription services. A provider cannot inherit a clinical outcome simply by displaying the same ingredient name.
Turn the finding into a continuity conversation
Our practical interpretation is to make the next contact explicit. If treatment becomes difficult to afford, ask the prescribing team who will review the clinical options and when that conversation can take place. Separately, ask billing what remains payable, whether a membership continues during a pause, and how cancellation affects access to records. A clinical decision and an account change are two different tasks; completing one does not reliably complete the other.
A useful written handoff identifies the current prescriber, the receiving clinician if there is one, the records being transferred, and the person responsible for following up. It should also identify how you can ask a clinical question while the transfer is unresolved. This is a service-planning suggestion, not a claim tested in STEP 1. Do not improvise dose changes to make the timing of billing and delivery line up.
Our provider comparison guides help you compare those service arrangements. The Form Health review is one place to examine scheduled follow-up and transition questions; inclusion here is not an endorsement for an individual patient. Use the provider checklist to keep clinical access and financial obligations on separate lines.
What to bring to the next appointment
Bring the question that is actually driving the decision: cost, unwanted effects, a change in goals, a move, or uncertainty about the benefit. A vague request to “come off treatment” leaves the clinician without useful context. Ask what would need reassessment, which changes should prompt contact, and who will own follow-up. The answer may differ between people even when they have used the same medicine.
For planning, compare a full year of known service and medication costs in the care planner, leaving unknown amounts visibly unknown. This does not decide whether treatment should continue. It makes the administrative constraint easier to explain. The central lesson is not a lifelong prescription rule: an endpoint in a weight-loss chart should not become an endpoint in communication.